Inactivating GGTase-I reduces disease phenotypes in a mouse model of K-RAS-induced myeloproliferative disease

Leukemia

Volumn 25, Issue 1, 2011, Pages 186-189

  Sjogren, A K M ^a   Andersson, K M E ^a   Khan, O ^a   Olofsson, F J ^a   Karlsson, C ^a   Bergo, M O ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DOUBLE STRANDED RNA; GENOMIC DNA; GERANYLGERANYLTRANSFERASE TYPE I; PROTEIN; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; CARCINOGENESIS; CONTROLLED STUDY; FETUS LIVER CELL; GENE EXPRESSION; GENE INACTIVATION; GENE MUTATION; GENE TARGETING; GENE TRANSFER; GENOTYPE; INJECTION; LETTER; LIVER CELL; MOUSE; MYELOPROLIFERATIVE DISORDER; NONHUMAN; ONCOGENE K RAS; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN PRENYLATION; TRANSGENE; WESTERN BLOTTING;

EID: 78651279264     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.242     Document Type: Letter

References (12)

1. Tigris Pharmaceuticals. First patient dosed in phase I clinical trial of Tigris Pharmaceuticals' GGTI-2418. Press release. Bonita Springs, FL, 1 May 2009. Accessed September 2009. Available at: http://www.tigrispharma.com/pr- 050109.html.
2. Lobell RB, Omer CA, Abrams MT, Bhimnathwala HG, Brucker MJ, Buser CA et al. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models. Cancer Res 2001; 61: 8758-8768.
3. Sun J, Ohkanda J, Coppola D, Yin H, Kothare M, Busciglio B et al. Geranylgeranyltransferase I inhibitor GGTI-2154 induces breast carcinoma apoptosis and tumor regression in H-Ras transgenic mice. Cancer Res 2003; 63: 8922-8929.
4. Sjogren AK, Andersson KM, Liu M, Cutts BA, Karlsson C, Wahlstrom AM et al. GGTase-I deficiency reduces tumor formation and improves survival in mice with K-RAS-induced lung cancer. J Clin Invest 2007; 117: 1294-1304.
5. Braun BS, Tuveson DA, Kong N, Le DT, Kogan SC, Rozmus J et al. Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proc Natl Acad Sci USA 2004; 101: 597-602.
6. Chan IT, Kutok JL, Williams IR, Cohen S, Kelly L, Shigematsu H et al. Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. J Clin Investig 2004; 113: 528-538.
7. Wahlstrom AM, Cutts BA, Liu M, Lindskog A, Karlsson C, Sjogren AK et al. Inactivating Icmt ameliorates K-RAS-induced myelo-proliferative disease. Blood 2008; 112: 1357-1365.
8. Kindler T, Cornejo MG, Scholl C, Liu J, Leeman DS, Haydu JE et al. K-RasG12D-induced T-cell lymphoblastic lymphoma/leukemias harbor Notch1 mutations and are sensitive to gamma-secretase inhibitors. Blood 2008; 112: 3373-3382.
9. Zhang J, Wang J, Liu Y, Sidik H, Young KH, Lodish HF et al. Oncogenic Kras-induced leukemogeneis: hematopoietic stem cells as the initial target and lineage-specific progenitors as the potential targets for final leukemic transformation. Blood 2009; 113: 1304-1314.
10. Sabnis AJ, Cheung LS, Dail M, Kang HC, Santaguida M, Hermiston ML et al. Oncogenic Kras initiates leukemia in hematopoietic stem cells. PLoS Biol 2009; 7: e59.
11. 1 and induces p21(WAF1/CIP1/SDI1) in a p53-independent manner. J Biol Chem 1997; 272: 27224-27229.
12. Watanabe M, Fiji HD, Guo L, Chan L, Kinderman SS, Slamon DJ et al. Inhibitors of protein geranylgeranyltransferase I and Rab geranylgeranyltransferase identified from a library of allenoate-derived compounds. J Biol Chem 2008; 283: 9571-9579.